ReviewAmerican journal of cancer research2018
Circulating biomarkers for early diagnosis of pancreatic cancer: facts and hopes.
Review in American journal of cancer research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Systematic Review of Cost-Effectiveness Studies on Pancreatic Cancer Screening.Current oncology (Toronto, Ont.) · 2025Pooled it
- Inflammatory cytokines and combined biomarker panels in pancreatic ductal adenocarcinoma: Enhancing diagnostic accuracy.PloS one · 2019Trial
- Confirmatory Clinical Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma.Current oncology (Toronto, Ont.) · 2025Article
- Oral and fecal microbiome alterations in pancreatic cancer: insights into potential diagnostic biomarkers.BMC microbiology · 2025Article
- Diagnosis and Management of Functional Pancreatic Neuroendocrine Tumors in Children-A Systematic Review.Diagnostics (Basel, Switzerland) · 2025Review
- Machine learning models for pancreatic cancer diagnosis based on microbiome markers from serum extracellular vesicles.Scientific reports · 2025Article
- The cross-talk between the macro and micro-environment in precursor lesions of pancreatic cancer leads to new and promising circulating biomarkers.Journal of experimental & clinical cancer research : CR · 2024Review
- Robust and consistent biomarker candidates identification by a machine learning approach applied to pancreatic ductal adenocarcinoma metastasis.BMC medical informatics and decision making · 2024Article
- Clinical significance of genomic sequencing of circulating tumour cells (CTCs) in cancer.The journal of liquid biopsy · 2024Review
- Evolving utility of exosomes in pancreatic cancer management.World journal of methodology · 2023Review
- An integrated computational biology approach defines the crucial role of TRIP13 in pancreatic cancer.Computational and structural biotechnology journal · 2023Article
- Progress on diagnostic and prognostic markers of pancreatic cancer.Oncology research · 2023Review
- Smaller size packs a stronger punch - Recent advances in small antibody fragments targeting tumour-associated carbohydrate antigens.Theranostics · 2023Review
- Role of circulating exosomal biomarkers and their diagnostic accuracy in pancreatic cancer.JGH open : an open access journal of gastroenterology and hepatology · 2023Article
- Developing and validating a survival prediction model based on blood exosomal ceRNA network in patients with PAAD.BMC medical genomics · 2022Article
- Review
- Current Screening Strategies for Pancreatic Cancer.Biomedicines · 2022Review
- Proteomic analysis of serum proteins in children with brain death.Translational pediatrics · 2022Article
- Article
- Integrated bioinformatics analysis shows integrin alpha 3 is a prognostic biomarker for pancreatic cancer.Open medicine (Warsaw, Poland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer (PC) is characterized by extremely high mortality and poor prognosis, which are largely ascribed to difficulties in early diagnosis and limited therapeutics. Although there is a sufficient window for intervention before preneoplastic lesions progress to invasive disease, effective early detection of PC remains difficult using current biomarkers and imaging techniques. Biomarkers with satisfactory diagnostic efficacy and convenient analysis methods are urgently required. In this review, we summarized recent advances in the identification of biomarkers in circulation for early detection of PC. A number of novel circulating biomarkers, such as metabolites, cell-free DNA (cfDNA), noncoding RNA, and exosomes, that show promising diagnostic value have been discovered using advances in sequencing techniques and "omics" analyses. Panels comprising several biomarkers may also exhibit better diagnostic performance. In the future, we need more efficient circulating biomarkers for the identification of noninvasive precursor lesions and early disease. Collaborative large-scale studies are also required to show the clinical validity and applicability of potential biomarkers.
Indexed as
Identifiers
29636993PMC5883088What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.